Literature DB >> 21876434

Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases.

Xiao-Min Yu1, Yin Wan, Rebecca S Sippel, Herbert Chen.   

Abstract

OBJECTIVE: The purpose of this study was to identify the risk factors that predict papillary thyroid microcarcinoma (PTMC)-related death in a large patient population to determine which patients need aggressive treatment.
BACKGROUND: The management of PTMC is controversial and ranges from observation to total thyroidectomy. The lack of consensus is predominantly due to the general excellent overall prognosis, thereby requiring a large cohort to delineate differences in outcome.
METHODS: All papillary thyroid cancer patients with tumor size of 1 cm or less in the Surveillance, Epidemiology and End Results Cancer Database from 1988 to 2007 were identified. Outcomes, including overall and disease-specific survival, were compared, and different risk groups were evaluated by multivariate analysis.
RESULTS: A total of 18,445 cases of PTMC with surgery were identified. The 10-year and 15-year overall survivals were 94.6% and 90.7%, respectively, while disease-specific survivals were 99.5% and 99.3%. Age greater than 45 years, male sex, African American or minority race, node metastases, extrathyroidal invasion, and distant metastases were stratified to be significant risk factors for overall survival. There were 49 thyroid cancer-related deaths. Forty-five (92%) of the 49 patients had at least 2 risk factors, and 51% of these 49 patients had 3 or more risk factors (vs 5.7% in the rest of the cohort, P < 0.001).
CONCLUSIONS: Although PTMC is generally associated with an excellent prognosis, 0.5% patients may die of PTMC. The presence of 2 or more risk factors is strongly associated with cancer-related mortality and can help to identify patients who should be considered for more aggressive management.

Entities:  

Mesh:

Year:  2011        PMID: 21876434     DOI: 10.1097/SLA.0b013e318230036d

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  94 in total

Review 1.  Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Juan J Sancho; Thomas W Jay Lennard; Ivan Paunovic; Frédéric Triponez; Antonio Sitges-Serra
Journal:  Langenbecks Arch Surg       Date:  2013-12-19       Impact factor: 3.445

Review 2.  Observation for newly diagnosed micro-papillary thyroid cancer: is now the time?

Authors:  F Pacini
Journal:  J Endocrinol Invest       Date:  2014-10-26       Impact factor: 4.256

3.  Ultrasound-guided percutaneous laser ablation of unifocal T1N0M0 papillary thyroid microcarcinoma: Preliminary results.

Authors:  Wei Zhou; Shan Jiang; Weiwei Zhan; Jianqiao Zhou; Shangyan Xu; Lu Zhang
Journal:  Eur Radiol       Date:  2016-11-16       Impact factor: 5.315

Review 4.  [Differentiated thyroid cancer].

Authors:  V Tiedje; K W Schmid; F Weber; A Bockisch; D Führer
Journal:  Internist (Berl)       Date:  2015-02       Impact factor: 0.743

Review 5.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

6.  Lymph node metastases do not impact survival in follicular variant papillary thyroid cancer.

Authors:  David F Schneider; Dawn Elfenbein; Ricardo V Lloyd; Herbert Chen; Rebecca S Sippel
Journal:  Ann Surg Oncol       Date:  2014-08-05       Impact factor: 5.344

Review 7.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

8.  Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine.

Authors:  P W Rosario; G Mourão; M R Calsolari
Journal:  J Endocrinol Invest       Date:  2018-10-23       Impact factor: 4.256

Review 9.  The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma.

Authors:  Roberto Vita; Antonio Ieni; Giovanni Tuccari; Salvatore Benvenga
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

10.  Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases.

Authors:  Xiao-Min Yu; David F Schneider; Glen Leverson; Herbert Chen; Rebecca S Sippel
Journal:  Thyroid       Date:  2013-09-11       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.